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ABSTRACT: In this study, the phase diagram of the ternary system of
ezetimibe−simvastatin−fenofibrate was established. It has been proven
that the ternary composition recommended for the treatment of mixed
hyperlipidemia forms a eutectic system. Since eutectic mixtures are
characterized by greater solubility and dissolution rate, the obtained result
can explain the marvelous medical effectiveness of combined therapy.
Considering that another well-known method for improving the aqueous
solubility is amorphization, the ternary system with eutectic concentration
was converted into an amorphous form. Thermal properties, molecular
dynamics, and physical stability of the obtained amorphous system were
thoroughly investigated through various experimental techniques com-
pared to both: neat amorphous active pharmaceutical ingredients
(considered separately) and other representative concentrations of ternary
mixture. The obtained results open up a new way of selecting the therapeutic concentrations for combined therapies, a path that
considers one additional variable: eutecticity.
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1. INTRODUCTION
Mixed hyperlipidemia is a significant risk factor for the
development of cardiovascular diseases.1 Dietary modification
and increased physical activity are the first recommended
therapy to modify the abnormal level of the lipids in the
bloodstream.2 Unfortunately, in many cases, lifestyle changes
are not enough to overcome this problem. Therefore, besides a
healthy diet, regular physical activity, alcohol abstinence, and
smoking cessation, the use of lipid-lowering drugs is needed.3
There are many active pharmaceutical ingredients (APIs)
reducing the level of serum triglycerides and cholesterol.
Among them, one can distinguish (i) statins, which inhibit 3-
hydroxy-3-methylglutaryl coenzyme A reductase, and thereby
block the cholesterol synthesis;4,5 (ii) fibrates, which activate
peroxisome proliferator-activated receptors leading to induce
the transcription of genes facilitating lipid metabolism;6 and
(iii) cholesterol absorption inhibitors working in the intestinal
brush border membrane such as ezetimibe (EZB).7 Despite a
large number of cholesterol-lowering APIs, the National
Cholesterol Education Program Adult Treatment Panel III
highlights that the monotherapy of any known drug might not
be sufficient to treat mixed hyperlipidemia properly.8
Consequently, combined drug therapy is recommended.9
It has been proven, that coadministration of fenofibrate
(FEN) and statin is more effective in controlling atherogenic
dyslipidemia in patients with type 2 diabetes mellitus,
metabolic syndrome, or mixed dyslipidemia than the
administration of either drug alone.10,11 In a similar patient
population, the lipid-lowering effects on low-density lip-
oprotein cholesterol (LDL-C) and triglycerides were signifi-
cantly greater with the coadministration of EZB and FEN
compared to each monotherapy.12 Moreover, a multitude of
clinical studies proved that the addition of a cholesterol
absorption inhibitor to statin therapy reduces LDL-C and total
cholesterol levels much more effectively than at least a double
dose of statin.13 As Bays et al. showed that the coadministra-
tion of 10 mg of EZB and 10 mg of simvastatin (SVT) results
in a similar reduction in plasma LDL-C level to 80 mg of SVT
alone.14 Since any binary combination of statins, fibrates, and
cholesterol absorption inhibitors brings improved medical
effectiveness in comparison to the monotherapy, Farnier et al.
suggested treating mixed hyperlipidemia with a ternary drug
composition.2 Clinical trials on 611 patients have shown that
coadministration of SVT (20 mg), EZB (10 mg), and FEN
(160 mg) effectively improved the overall atherogenic lipid
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profile, which could not be achieved in mono or binary
therapy.
Both EZB, SVT, and FEN belong to Biopharmaceutics
Classification System (BCS) class II.15−19 It means that all
these APIs, on the one hand are characterized by good
permeability, but on the other hand, have a problem with poor
aqueous solubility. Low water solubility and slow dissolution
rate of crystalline APIs in the gastrointestinal tract are the
major obstacles impeding the development of drug formula-
tions for oral delivery.20,21 Therefore, many efforts are
currently devoted to improving the solubility-limited bioavail-
ability of marketed BCS class II pharmaceuticals.22−24 Several
methods might help in reaching this goal.25 One of them is
based on the formation of eutectic systems.26 A eutectic
mixture is defined as a mixture of two or more components
that do not interact to form a new chemical compound but, at
certain ratios are miscible in the molten state, usually at a
temperature lower than the melting points of either of their
constituents.27 It has been many times reported that eutectic
concentrations play a key role in improving the absorption of
many APIs by increasing their solubility and dissolution
properties.28,29 With that in mind, one might wonder whether
or not the marvelous therapeutic properties observed by
Farner et al. during the combined therapy with EZB, SVT, and
FEN are connected with the accidental employment of the
ternary eutectic concentration of these APIs. Finding the
answer to this question is the first goal of this paper. To
achieve this aim, the ternary phase diagram of EZB, SVT, and
FEN was determined both experimentally and theoretically.
It has to be mentioned that another very well-known path
leading to the water solubility improvement of the crystalline
APIs is their conversion to amorphous form.30−37 Thus, the
second goal of this paper is to prepare and characterize the
disordered counterparts of the investigated ternary composi-
tions. Working with amorphous APIs, one cannot forget that
such systems have unfortunately, one disadvantage blocking
their widespread use. Namely, such systems are physically
unstable, and thus during the time of manufacturing,
transportation, or storage, they might revert to their initial,
i.e., crystalline form.38−42 Hence the third goal of this study
was to examine the effect of eutectic concentration on the
physical stability improvement of the ternary amorphous
system. To achieve this goal, a series of: (i) short-term time-
dependent dielectric experiments at elevated temperature
conditions as well as (ii) long-term diffraction studies under
standard storage conditions were performed.
2. MATERIALS AND METHODS
2.1. Materials. EZB of purity greater than 99% and
molecular mass Mw = 409.4 g/mol was purchased from
Polpharma (Starogard Gdanśki, Poland). This pharmaceutical
is described chemically as ((3R,4S)-1-(4-fluorophenyl)-3-
[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxy-
phenyl) azetid in-2-one). SVT of purity greater than 98% and
molecular mass Mw = 418.6 g/mol was purchase from
ATOMAX and is described chemically as butanoic acid, 2,2-
dimethyl-(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-di-
methyl-8-[2[(2R,4R)tetra hydro-4-hydroxy-6-oxo-2H-pyran-2-
yl] ethyl]-1-na-phthalenyl ester. FEN, which is described
chemically as 2-[4-(4-Chlorobenzoyl) phenoxy]-2-methylpro-
panoic acid isopropyl ester (Mw = 360.83 g/mol), was
purchased from Sigma-Aldrich with purity greater than 99%.
All neat APIs were used as received. Their chemical structures
are presented in Figure 1.
2.2. Differential Scanning Calorimetry. The thermal
properties of neat, both crystalline and amorphous EZB, SVT,
and FEN drugs, as well as their binary and ternary systems
were examined by a Mettler−Toledo DSC 1 STARe System
(Columbus, OH, USA) equipped with an HSS8 ceramic
sensor and 120 thermocouples. The instrument was calibrated
for temperature and enthalpy using indium and zinc standards.
The melting point was determined as: (i) the onset
temperature in the case of neat APIs and the solidus transition
in the mixtures, or (ii) the peak maximum temperature in the
case of the mixture’s liquidus transition. At the same time, the
glass transition temperature (Tg) was determined as the
midpoint of the heat capacity increment. The samples were
measured in an aluminum crucible (40 μL). All crystalline
mixtures were measured with a rate of 10 K/min, while during
the studies of amorphous samples, two heating rates (5 and 10
K/min) were employed. Each experiment was at least
performed in duplicate.
2.3. X-ray Diffraction. Long-term X-ray diffraction (XRD)
experiments were performed for ternary amorphous samples
stored at room temperature and relative humidity RH ≈ 40%
on a Rigaku-Denki D/MAX RAPID II-R diffractometer
(Rigaku Corporation, Tokyo, Japan) equipped with a rotating
Ag anode, an incident beam (002) graphite monochromator,
and an image plate detector in the Debye−Scherrer geometry.
The wavelength of the incident beam λ was 0.5608 Å. The
pixel size was 100 μm × 100 μm, and the beam width on the
sample was 0.3 mm. Measurements were performed for
powder samples enclosed in borosilicate glass capillaries, and
the background intensity from empty capillary was collected
and subtracted. The two-dimensional diffraction patterns were
converted into one-dimensional intensity data versus the
scattering angle. The temperature-dependent XRD measure-
ments were performed using an Oxford Cryosystem 800 unit.
2.4. Broadband Dielectric Spectroscopy. The molec-
ular dynamics and the time-dependent isochronal physical
stability of the selected ternary amorphous EZB/SVT/FEN
systems were measured utilizing a Novocontrol GMBH Alpha
dielectric spectrometer (Montabaur, Germany). Dielectric
spectra were registered in a broad frequency range from 10−1
to 107 Hz. During the nonisothermal dielectric experiments,
the samples were heated from temperature T = Tg to T = T(τα
= 0.2 ns) with a step of 2 K. While during isothermal (time-
dependent) studies, the samples were stored under defined T
conditions (specific for each sample) for a longer period of
time during which spectra were registered every 600 s. The
temperature was controlled by a Quattro controller with
temperature stability better than 0.1 K. The systems were
measured in a parallel-plate cell made of stainless steel
(diameter of 15 mm, and 0.1 mm gap provided by silica
spacer fibers).
Figure 1. Chemical structures of EZB, SVT, and FEN.
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3. RESULTS AND DISCUSSION
3.1. Determination of Binary Eutectic Mixtures of
EZB-SVT, EZB-FEN, and SVT-FEN Systems. To determine
the eutectic concentrations of three binary systems: EZB/SVT,
EZB/FEN, and SVT/FEN, the physical mixtures of these
systems, with the mass ratio equal to 1:9, 2:8, 3:7, 4:6, 5:5, 4:6,
3:7, 2:8, and 9:1, were investigated utilizing differential
scanning calorimetry (DSC). During these experiments, the
samples were heated up from 303 to 445, 440, or 420 K in the
case of EZB/SVT, EZB/FEN, and SVT/FEN, respectively.
The obtained results together with the DSC curves of neat
APIs are presented in panels a, c, and e of Figure 2. As can be
seen, the thermograms are typical for eutectic systems. In most
cases, one can observe the presence of two melting
endotherms.43 The onset temperature of the first peak (i.e.,
the one located at a lower temperature) does not change with
the mixture content. This temperature is called the solidus
temperature below which the mixture is in its solidfully
crystallinestate. The temperature of the second melting
endotherm shifts toward or away from the solidus temperature,
depending on the drug concentration. Above this second
peakcalled liquidus temperaturethe binary mixtures are in
the fully molten state.44 By analyzing the recorded thermo-
grams, the melting temperatures of the binary drug−drug
mixtures were determined. The obtained results were then
used to construct the phase diagrams (see black squares in
Figure 2b,d,f).
As can be seen, all three investigated binary drug−drug
compositions form eutectic systems. The concentration
corresponding to a single melting endotherm is 35 wt % of
EZB (i.e., xEZB = 0.645), 10 wt % of EZB (i.e., xEZB = 0.089),
and 20 wt % (i.e., xSVT = 0.177) of SVT for EZB/SVT, EZB/
Figure 2. DSC thermograms of the crystalline physical mixtures of: (a) ezetimibe−simvastatin (EZB/SVT), (c) ezetimibe−fenofibrate (EZB/
FEN), and (e) simvastatin−fenofibrate (SVT/FEN) together with their phase diagrams (b, d, f, respectively) which were constructed on the basis
of both experimentally determined data (black squares) and theoretical data obtained based on the Schröder−Van Laar equation (black dashed
lines).
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FEN, and SVT/FEN, respectively. In addition to the
experimentally determined mole fraction dependence of
liquidus temperatures presented in Figure 2b,d,f as black
points, the theoretical values were calculated by means of the















where ΔH0 represents the heat of fusion (J·mol−1), T0 is the
melting point of one of the pure drugs in the mixture, T is the
Figure 3. (a) Ternary plot illustrating by points the investigated compositions of EZB/SVT/FEN; colors represent the concentration areas where
during heating one, two, or three melting endotherms were registered (onered area, twogreen area, threeblue area); (b) the DSC
thermograms of the representative systems from those three areas (c) the XRD patterns of the EZB/SVT/FEN sample for 60/30/10 concentration
as a function of temperature from 295 to 415 K. Diffractograms for neat crystalline FEN, SVT, and EZB are also shown. Melting of FEN, SVT, and
EZB is observed as the Bragg peaks disappear corresponding to their crystalline phases at 350, 383, and 415 K, respectively.
Figure 4. (a) 3D phase diagram of the EZB/SVT/FEN system constructed based on the experimental data; (b-d) 2D layers represents three
melting areas presented in panel a; (e) 3D phase diagram of the EZB/SVT/FEN system constructed based on the theoretical data.
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melting point of the binary mixture at a specific mole fraction,
x, and R represents the gas constant. The theoretically
obtained liquidus curves are presented as dashed lines in
panels b, d, and f of Figure 2. Both experimental and
theoretical mole fraction dependences of liquidus temperature
are in good agreement, while the error of the eutectic points
determined from both these methods is less than 3.5%.
Because the eutecticity of EZB/FEN and SVT/FEN systems is
not so obvious as it is in the case of EZB/SVT more detailed
data are shown in the Supporting Information (see Figures S1
and S2).
3.2. Determination of the Ternary Eutectic EZB−
SVT−FEN System. In order to determine the ternary eutectic
point of the EZB/SVT/FEN system, 37 mixtures having
various concentrations of these drugs have been prepared and
investigated utilizing DSC. Points in Figure 3a represents the
investigated concentrations. During these experiments, samples
were heated up from 298 to 440 K with a rate of 10 K/min.
The selected DSC thermograms of the representative samples
are presented in Figure 3b together with the thermograms of
neat APIs. As can be seen, depending on the drug content, the
thermogram of EZB/SVT/FEN might reveal one, two, or three
endothermal events. The concentrations at which three
thermal events were observed is marketed in panel a of Figure
3 as a blue area. The green area represents concentrations at
which two melting endotherms were registered, while the red
color corresponds to the eutectic concentration, revealing a
single sharp thermal event. By performing a temperature-
dependent XRD experiment on the sample for which the three
thermal events were registered, it was possible to identify that
the first thermal event corresponds to the melting of FEN, the
second to the melting of SVT, while the third to the EZB’s
melting (see panel c of Figure 3). Herein, it is worth
emphasizing that the formation of co-crystals of the EZB/
SVT/FEN system can be excluded based on the performed
thermal analysis. It is because the cocrystals melt in the
temperature range between the neat component melting.46−48
In comparison, all investigated thermograms reveal one
melting endotherm having an onset at a lower temperature
than the melting of each neat sample (compare the
thermograms of neat APIs and the representative mixtures
presented in panel b of Figure 3).
The 3D phase diagram constructed based on the
experimental data is presented in panel a of Figure 4. To
better visualize the concentration dependence of melting
temperatures, the graph was divided into three 2D layers (see
panels b, c, and d of Figure 4). From the ternary phase
diagram, the eutectic point of EZB/SVT/FEN was found at a
10/20/70 mass ratio.
Since the precision in the determination of the eutectic point
by the experimental method is associated with the number of
investigated points (samples), the liquidus curves of the
investigated system have also been calculated from the
enthalpy of fusion and melting point of the neat components
by the Schröder−Van Laar equation (see eq 1). The predicted
concentration dependence of the liquidus temperature and,
consequently, ternary eutectic point of the EZB/SVT/FEN
system are presented as a 3D phase diagram in panel e of
Figure 4. Comparing the ternary eutectic concentration
determined from the experimental and theoretical approach,
one can note that both these methods give similar results (i.e.,
there are no more than 5% differences between theoretically
and experimentally determined eutectic concentration). The
obtained results clearly indicate that during the combined
therapy of EZB/SVT/FEN, which was proposed by Farner et
al.,2 the eutectic compositions were not employed. Never-
theless, it is worth noting that the concentration of this system
(i.e., EZB5.3/SVT10.5/FEN84.2) is close (±15%) to the
concentration of the eutectic mixture determined in this paper.
Consequently, it would be extremely interesting to check the
therapeutic effectiveness of the EZB10/SVT20/FEN70
(eutectic) system for which the solubility, dissolution rate,
and bioavailability should be better than the one proposed as a
therapeutic. Nevertheless, because another competing method
to the eutectic formation method to improve the solubility of
BCS class II pharmaceuticals is amorphization, in the further
part of the paper we will convert ternary EZB/SVT/FEN
systems to the amorphous form and investigate its
physicochemical properties.
3.3. Thermal Properties of Ternary Amorphous EZB/
SVT/FEN Systems. The quench-cooled neat amorphous EZB,
SVT, and FEN, when measured by means of DSC with a rate
of 10 K/min, have a glass transition (Tg) at temperature equal
to 336, 306, and 254 K, respectively (see Figure 5). Comparing
the thermograms of the neat APIs, one can note that only FEN
re-crystallizes during further heating with this rate, i.e., on the
DSC curve both the exothermal event associated with
recrystallization as well as the endothermal process connected
with melting of the devitrified fraction of the samples are
visible. To assess the tendency toward the recrystallization of
the other APIs, slower heating rates, equal to 5 and 2.5 K/min,
were employed. As can be seen the intermediate tendency
toward recrystallization reveals EZB. Namely, the recrystalliza-
tion of this API was registered at 415 K, when measured with a
rate of 5 K/min, while, the greatest physical stability shows
SVT, because no exothermal event was obtained even at 2.5 K/
min heating rate.
To find out how the thermal properties of the mentioned
pharmaceuticals vary when the drugs are mixed together, 37
ternary amorphous mixtures containing various mass ratios of
EZB, SVT, and FEN were measured using the DSC technique.
All the measurements were carried out from 240 to 440 K at
the rate of 10 and 5 K/min. The DSC thermograms of eight of
Figure 5. DSC thermograms of neat amorphous FEN (blue line),
SVT (green lines), and EZB (red lines) measured with heating rates
of 10, 5, and 2.5 K/min.
Molecular Pharmaceutics pubs.acs.org/molecularpharmaceutics Article
https://doi.org/10.1021/acs.molpharmaceut.1c00485
Mol. Pharmaceutics XXXX, XXX, XXX−XXX
E
the most representative samples are depicted in Figure 6a. As
can be seen, the mixtures containing EZB, SVT, and FEN are
characterized by a single glass transition event suggesting a lack
of phase separation. It has been many times reported that if
components are not or only partially miscible, the DSC curve
of its amorphous composition should reveal two or more
separate Tg values (each belonging to the appropriate sample
fraction).49 On the basis of all obtained data at the heating rate
of 10 K/min, the concentration dependence of the glass
transition temperature for the EZB/SVT/FEN system has
been constructed, and is presented in Figure 6b. As can be
seen, the Tg value strongly depends on the system
concentration. It increases with increasing EZB or SVT
content. If the mass fraction of FEN is higher than 0.3, the
composition is characterized by Tg lower than the room
temperature. On the other hand, the highest Tg values possess
the systems having a mass fraction of EZB and SVT higher
than 0.7 and 0.3, respectively.
It should be pointed out that none of the tested samples
showed a tendency toward recrystallization both at 10 and 5
K/min heating rates. This result indicates that the physical
stability of neat FEN and EZB was improved by the presence
of the other APIs, regardless of whether the antiplasticization
or plasticization effect was exerted.
In the further part of this paper, we will precisely investigate
how the physical stability of the amorphous form of the
investigated APIs changes depending on the mixture
concentration. For that purpose, two kinds of experiments
have been performed. The first approach considers the fact that
the physical stability of amorphous APIs strongly depends on
its molecular mobility. Consequently, all systems were
examined under the same isochronal conditions (i.e., τα =
const.). The second approach takes into account that all
pharmaceutical products are finally stored under standard
storage conditions (i.e., T = 298 K and RH = 40%). Thus, the
investigated systems were stored for longer period of time at
that particular, well defined conditions, and every once in a
Figure 6. (a) DSC thermograms of eight representative ternary amorphous EZB/SVT/FEN systems, (b) the concentration dependence of the glass
transition temperature of the EZB/SVT/FEN system.
Figure 7. (a) Dielectric loss spectra collected above the glass transition temperature of ternary amorphous EZB 5.3/SVT 10.5/FEN 84.2 systems.
(b) Temperature dependence of the structural relaxation times determined by using the BDS technique for pure amorphous EZB (gray squares),
pure amorphous SVT (gray triangles), pure amorphous FEN (gray circles), and their ternary mixtures that contain various mass ratios of: EZB 70/
SVT 10/FEN 20 (orange circles), EZB 40/SVT 40/FEN 20 (yellow squares), EZB 10/SVT 70/FEN 20 (dark green triangles), EZB 30/SVT 30/
FEN 40 (light green diamonds), EZB 40/SVT 10/FEN 50 (cyan hexagons), EZB 10/SVT 40/FEN 50 (light blue pentagons), EZB 10/SVT 20/
FEN 70 (dark blue triangles), and EZB 5.3/SVT 10.5/FEN 84.2 (navy stars). Solid black lines are the VFT1 fits, dashed red line marks the region,
where τα = 0.63 μs, while red arrows represent the temperatures which corresponds to τα = 0.63 μs for each sample.
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while, their stability was investigated by means of the XRD
technique.
3.4. Molecular Dynamics of the Selected Supercooled
Ternary System of EZB/SVT/FEN. In this section, the
molecular mobility of eight selected ternary systems of EZB/
SVT/FEN was investigated. The selection considered the most
representative concentrations (see points in Figure 6b) among
which both the ternary eutectic and therapeutic systems were
included. The aim of these experiments was twofold. On the
one hand, the effect of additives on the molecular dynamics
and the tendency toward recrystallization of the neat APIs
were investigated. While on the other hand, the results of these
studies allow us the proper selection of the storage conditions
of the samples in the further stability tests in such a way that
the systems are characterized by a constant relaxation time. To
investigate the differences in the molecular mobility of the
investigated ternary amorphous systems, the dielectric loss
spectra of these samples were measured by means of
broadband dielectric spectroscopy (BDS). The dielectric
measurements were performed in the wide frequency (from
10−1 to 107 Hz) and temperature range (from T = Tg to T =
T(τα = 0.2 ns). The representative spectra of the ternary EZB/
SVT/FEN composition having documented the excellent
therapeutic effect on mixed hyperlipidemia treatment are
shown in Figure 7a.
The dielectric loss spectra of all investigated ternary systems
exhibit two features: the dc-conductivity associated with the
translational motions of ions and the structural (α) relaxation
process related to the cooperative rearrangement of the drug
molecules. As shown in Figure 7a, the α-relaxation mode
moves toward a higher frequency with increasing temperature,
indicating increased molecular mobility. It is also worth noting
that none of the investigated systems reveal a drastic drop in
the intensity of the structural relaxation peak during the
heating procedure. This indicates an absence of the cold
crystallization of the mixtures, which is especially interesting
since, according to the literature reports, neat amorphous EZB
and FEN, during similar dielectric experiments, would
recrystallize.34,50,51 The onset of the recrystallization process
was registered at temperatures at which the maximum of the α-
relaxation was located at a frequency from the range 104−105
Hz. Since devitrification of the APIs from the ternary mixtures
was not observed, one can conclude that the enhancement of
the physical stability is mainly driven by a thermodynamic
factors (i.e., configurational entropy, enthalpy, or Gibbs free
energy). If a kinetic factor (i.e., molecular mobility) would play
here a key role, one could expect the presence of the
recrystallization at similar, i.e., isochronal, conditions as in the
case of neat APIs.
From the analysis of dielectric loss spectra, the temperature
dependencies of the structural relaxation times (τα(T)) for all
investigated ternary compositions were obtained. The
comparison of the τα(T) dependencies of the measured
ternary systems and neat APIs is presented in Figure 7b. The
relaxation times were determined from fitting of dielectric
spectra by the Havriliak−Negami (HN) function with the dc
conductivity term, which is defined as follows:52

















where ε∞ is the high-frequency limit permittivity, ε0 denotes
the permittivity of vacuum, Δε is the dielectric strength, ω is
equal to 2πf, τHN is the HN relaxation time, and a and b
represent symmetric and asymmetric broadening of the
relaxation peak. By employing the determined fitting
parameters, we finally calculated the τα values utilizing the
following equation:



































Usually, in the supercooled liquid region, the τα(T) shows
non-Arrhenius behavior and might be well parameterized by













where τ∞, T0, and B are the fitting parameters. Parameter τ∞ is
a pre-exponential factor denoting the upper limit of temper-
ature for τα, which is correlated to the vibrational frequency
(∼10−11 to 10−14 s). T0 is the Vogel temperature, which
corresponds to the state with infinite relaxation time, and B =
DT0, where D quantifies the deviation from the simple
Arrhenius behavior. Since it has been previously noted that the
temperature evolution of structural relaxation time of neat EZB
does not conform over the entire experimental temperature
range to a single VFT equation,34 thus prior to the fitting
procedure each τα(T) dependence was analyzed by the
derivative method proposed by Stickel.56 This approach
requires the employment of the operator [d(log(τα))/dT]
−1/2
Table 1. Comparison of the Values of Tg Obtained from DSC and BDS, Fragility Parameters, VFT1 Fitting Parameters, Tcross,
and T(τα = 0.63 μs) for Neat Amorphous EZB, SVT, and FEN Drugs, and Their Ternary Amorphous Mixtures at Mass Ratios
70/10/20, 40/40/20, 10/70/20, 30/30/40, 40/10/50, 10/40/50,10/20/70, and 5.3/10.5/84.2
sample Tg(DSC) [K] Tg(BDS) [K] mp τ∞ [s] B T0 [K] Tcross [K] T(τα = 0.63 μs) [K]
EZB 336 333 93 −11.81 ± 0.03 1130 ± 11 301.1 ± 0.3 355 388
SVT 305 303 91 −15.68 ± 0.13 2386 ± 51 244.0 ± 0.9 353
FEN 254 251 95 −13.52 ± 0.17 1465 ± 10 209.3 ± 1.0 298
70/10/20 313 311 102 −12.51 ± 0.08 1483 ± 30 266.5 ± 0.7 395 369
40/40/20 302 301 104 −12.93 ± 0.12 1576 ± 41 256.4 ± 1.0 382 357
10/70/20 291 290 98 −13.78 ± 0.09 1769 ± 33 242.4 ± 0.7 368 343
30/30/40 285 284 97 −12.75 ± 0.10 1514 ± 36 240.1 ± 0.8 355 340
40/10/50 283 282 95 −12.79 ± 0.08 1564 ± 27 237.1 ± 0.6 361 340
10/40/50 272 271 98 −13.18 ± 0.14 1553 ± 46 277.7 ± 1.0 344 325
10/20/70 265 263 97 −12.57 ± 0.09 1346 ± 25 223.1 ± 0.6 315
5.3/10.5/84.2 260 257 99 −12.55 ± 0.04 1280 ± 13 219.0 ± 0.3 307
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= (T − T0)B−1/2, which linearized the VFT equation.
Consequently, it was easy to determine the temperature
regions in which the experimental data were well para-
meterized by a single VFT. This method confirmed that in
almost all investigated ternary systems the obtained data had to
be fitted using two VFT functions to cover the entire
temperature range (except two concentrations with eutectic
and therapeutic properties, i.e., EZB10/SVT20/FEN70 and
EZB5.3/SVT10.5/FEN84.2). The temperature at which the
VFT1 and VFT2 intersect (Tcross), and all the fitting parameters
are shown in Table 1. Additionally, the VFT1 fits are presented
in Figure 7b as solid lines.
Because of the fact that VFT1 well describes the data in the
region below the crossover temperature, it was utilized to
estimate the kinetic glass transition temperature of each ternary
system. The Tg value from BDS experiments was obtained
using the commonly known definition Tg = T(τα = 100 s).
These values are collected in Table 1, together with the Tg
values determined from DSC. As can be noted, the glass
transition temperature values determined by using two
different methods slightly differ. The observed discrepancy
between the kinetic and the calorimetric Tg values is associated
with the different heating rates used in these experiments.
Finally, the τα(T) dependences, determined from the
dielectric data, were utilized for selecting the appropriate
temperature conditions for further short-term physical stability
studies performed at elevated temperature conditions. For that
purpose, the straight line has been drawn at a fixed structural
relaxation time equal to 0.63 μs (see the red dashed line in
Figure 7b). Temperatures determined from the intersection of
the drawn line with the temperature dependences of the
samples structural relaxation times are collected in Table 1.
3.5. Physical Stability Studies of Selected Super-
cooled Ternary Systems Containing EZB, SVT, and FEN
under Isochronal Temperature Conditions. In this
section, the physical stability of neat APIs and five ternary
amorphous EZB/SVT/FEN systems were investigated and
compared with each other. All samples were measured under
temperature conditions at which their structural relaxation
time (τα) is equal to 0.63 μs. This particular condition was
chosen based on previously published physical stability data of
the neat EZB and FEN. According to the recalled data, EZB
and FEN were stored at a temperature at which τα = 0.63 μs
should fully recrystallize after ca. 2.5 and 4.5 h, respec-
tively.34,51 First, to make sure that the physical stability of neat
EZB and FEN is independent of the used batch as well as to
investigate the recrystallization tendency of neat SVT stored at
T = T(τα = 0.63 μs), the isothermal time-dependent dielectric
experiments of these three neat APIs were performed. During
these measurements, the spectra of the complex dielectric
Figure 8. (a-c) Dielectric spectra of the real parts of the complex dielectric permittivity collected during the time-dependent isothermal experiment
of: (a) EZB performed at 388 K, (b) FEN performed at 298 K, and (c) SVT performed at 353 K. (d) normalized dielectric constants ε′N of EZB
(squares), SVT (triangles), and FEN (circles) as a function of time from crystallization processes occurring at T = T(τα = 0.63 μs).
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permittivity ε*(ω) = ε′(ω) − iε″(ω) were investigated at
specified time intervals of 600 s. By utilizing the dielectric
spectroscopy, the recrystallization can be followed in both the
real (ε′) and imaginary (ε″) parts of the complex dielectric
permittivity, reflected by a decrease of the static permittivity
(εs) and reduction of the loss peak intensity with time,
respectively.57,58 For our purpose, the real part of complex
dielectric permittivity was selected for further analysis. The
obtained results are shown in Figure 8a-c.
As can be clearly seen, EZB recrystallizes the fastest among
the tested neat APIs, while SVT is characterized by the highest
physical stability. The progress of crystallization is usually




′ = ′ − ′
′ − ′ ∞
t(0) ( )
(0) ( )N (5)
where ε′(0) is the initial static dielectric permittivity, ε′(∞) is
the long-time limiting value, and ε′(t) is the value at time t.
The comparison of the normalized data plotted versus time is
shown in panel d of Figure 8. The obtained results indicate
that the crystallization half-life time (t0.5) of neat EZB, FEN,
and SVT stored at a temperature at which τα = 0.63 μs is equal
to 79, 114, and 330 min, while the entire devitrification takes 2,
4, and 25 h, respectively. Since the determined physical
stability times of both EZB and FEN are in good agreement
with the previously published data, one can conclude that the
sample batch has no impact on the tendency toward
recrystallization.
Knowing the physical stability of neat APIs at the chosen
isochronal conditions, we performed similar physical stability
experiments for the ternary compositions. The concentrations
selected for these studies correspond to the eutectic
concentration (EZB10/SVT20/FEN70), therapeutic concen-
tration proposed by Farnier et al. (EZB5.3/SVT10.5/
FEN84.2)2 and three representative concentrations which
τα(T) are presented in Figure 7b as cyan hexagons, light green
diamonds, and light blue pentagons (EZB40/SVT10/FEN50,
EZB10/SVT40/FEN50, and EZB30/SVT30/FEN40, respec-
tively). The other three representative concentrations
(EZB10/SVT70/FEN20, EZB40/SVT40/FEN20, and
EZB70/SVT10/FEN20) were not tested since temperatures
at which their τα = 0.63 μs are higher than the solidus
temperature. In order to determine the temperature appro-
priate for each investigated sample (i.e., temperature at which
τα = 0.63 μs) we used molecular dynamics data, described in
the above section, presented in Figure 7b. Since the time of
physical stability of the ternary system turned out to be much
longer than for neat APIs, the samples were left for a longer
period of time in the laboratory ovens and from time to time,
they were connected to the dielectric spectrometer in order to
register the progress of their recrystallization. When the
devitrification process ceased, the obtained data were
normalized in the same fashion as in the case of neat APIs.
The kinetic curves obtained for all investigated samples, i.e.,
both neat APIs and their five ternary compositions, are
compared in Figure 9.
As can be seen, the ternary composition having a therapeutic
concentration of the drugs (EZB 5.3/SVT 10.5/FEN 84.2)
recrystallizes the fastest among all investigated systems. The
half-life time of this compositions is equal to 10.5 h, while the
process ends after 13.5 h. The high content of FEN is probably
the main reason for the quicker devitrification of this system in
comparison to the neat SVT. It is worth noting that the other
ternary compositions become fully crystalline after a
significantly longer time than any investigated neat API. This
result, without a doubt, confirms the positive effect of
combining the tested pharmaceuticals on the physical stability
of their amorphous form.
To better visualize and consequently properly compare the
tendency of the investigated compositions toward devitrifica-
tion, the times of crystallization onset, half-life, and endset have
been presented in Figure 10.
As can be seen, EZB40/SVT10/FEN50 is the second-fastest
crystallizing system among those investigated. This result is not
surprisingthe system contains as much as 40% of EZB and
50% of FEN, which under similar conditions, crystallize much
faster than SVT (see the inset of Figure 10). The composition
of EZB10/SVT40/FEN50 reflects this dependence even
better. Namely, because of the much greater amount of SVT
than in the previous case, its devitrification takes a much longer
period of time. It is worth highlighting that the full crystallinity
of this system is reached even later than for EZB30/SVT30/
FEN40, which begins to devitrify ca. 10 h later than EZB10/
SVT40/FEN50. The latter composition has a smaller amount
of SVT than EZB10/SVT40/FEN50, which can easily explain
why its crystallization process is shorter. The only composition
Figure 9. Normalized dielectric constants ε′N of neat amorphous EZB (gray squares), SVT (gray triangles), and FEN (gray circles) as well as their
ternary amorphous systems containing 5.3/10.5/84.2 (navy stars), 10/20/70 (dark blue triangles), 10/40/50 (light blue pentagons), 40/10/50
(cyan hexagons),and 30/30/40 (green diamonds) mass ratio of EZB/SVT/FEN as a function of crystallization time occurring at T = T(τα = 0.63
μs).
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for which physical stability cannot be explained in a similar, as
the above, way is EZB10/SVT20/FEN70. It is worth recalling
that this particular concentration corresponds to the eutectic
system. Recently Kissi et al. showed that in the case of binary
amorphous drug−drug compositions of indomethacin−nap-
roxen, nifedipine−paracetamol, and paracetamol−celecoxib,
the highest physical stability was observed at ratios analogous
to the eutectic concentrations of the respective crystalline
mixtures.62 Taking this fact into account, one might conclude
that regardless of the amount of the ingredients, the specific
interactions, which on the one hand, are responsible for the
formation of eutectic in crystalline mixtures, play a significant
role in improving the physical stability of their amorphous
counterparts.
3.6. Long-Term Physical Stability Studies of Selected
Ternary Amorphous Systems Containing EZB, SVT, and
FEN at Room Temperature. In the previous section, the
physical stability of the representative amorphous mixtures of
EZB/SVT/FEN was studied at selected isochronal conditions
(τα = 0.63 μs). Without a doubt, such experiments are essential
from a cognitive point of view. Namely, they can help in
finding a true molecular origin of the inhibition of
recrystallization in the multicomponent amorphous systems.
However, during such studies, each sample is stored at totally
different temperature conditions (from 298 K in the case of
neat FEN up to 388 K for neat EZB). Thus, from a practical
point of view, it is also very important to investigate the
physical stability of the ternary amorphous systems under
conditions corresponding to the standard storage conditions
(i.e., constant temperature Troom = 298 K and relative humidity
RH = 40%). Having this in mind, we performed long-term
physical stability studies at such conditions for eight selected
ternary amorphous EZB/SVT/FEN systems (concentrations:
5.3/10.3/84.2, 10/20/70, 10/40/50, 40/10/50, 30/30/40, 10/
70/20, 40/40/20, and 70/10/20). These measurements were
realized by means of the XRD technique. The representative
XRD patterns obtained during these experiments are presented
in Figure 11. As can be seen in panel a of Figure 11, the
diffractograms of all freshly prepared systems are characterized
by broad, diffuse peak which confirms that the crystalline long-
range order was destroyed in the investigated samples. This
result proves that the tested ternary systems were fully
amorphous just after the applied amorphization procedure.
Next, the samples were left in a glow box, where humidity and
temperature were monitored. The XRD diffraction patterns of
these systems were collected once a week for the first month of
the experiment, and then once a month for next 5 months.
Data presented in panel b of Figure 11 indicate that the
composition with a ratio of 5.3/10.3/84.2 (therapeutic system
proposed by Farner et al.) begins to recrystallize the fastest
among all investigated ternary systems. We noticed the first
sign of its recrystallization just after 15 days after
amorphization. It should be noted that destabilization of this
system begins from FEN recrystallization.
The second sample for which the recrystallization was
observed during the performed studies is 40/10/50 (EZB/
SVT/FEN, respectively). The appearance of sharp Bragg’s
peaks in the XRD diffraction pattern of this composition was
registered 2 months after its amorphization. In this case, both
recrystallization of FEN and EZB from the composition was
noted. All other ternary amorphous systems do not reveal loss
of their physical stability even after 6 months of storage. It is
worth noting that the results obtained from long-term XRD
studies, are relatively consistent with the stability studies
performed at isochronal conditions by BDS. Namely, (i) the
fastest recrystallization was observed for the EZB/SVT/FEN
system with the concentration of 5.3/10.3/84.2, (ii) the
second least stable system was the one with 40/10/50
concentration, and (iii) the ternary amorphous system having
a concentration corresponding to the eutectic system (i.e.,
EZB10/SVT20/FEN70) is characterized by significantly
higher physical stability than the concentrations described
above. It should be pointed out that at the chosen experimental
conditions (Troom) some of the samples were measured in the
supercooled liquid, while the others at their glassy state
(compare the position of the red dashed line, which is marked
Troom in Figure 6a with the distance from Tg). Thus, from this
type of study, it is hard to draw conclusions about the impact
of the additives on the ternary amorphous system’s physical
stability.
Figure 10. Comparison of the crystallization onset, half-life time, and
endset of neat amorphous EZB, SVT, and FEN, as well as their
ternary amorphous systems containing 5.3/10.5/84.2, 40/10/50, 10/
40/50, 30/30/40, and 10/20/70 mass ratio of EZB/SVT/FEN.
Figure 11. Representative XRD patterns of the selected ternary
amorphous systems of EZB/SVT/FEN measured: (a) just after
amorphization and (b) after long-term storage of the samples at T =
298 K.
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4. CONCLUSIONS
In this article, the phase diagrams of three binary EZB/SVT,
EZB/FEN, and FEN/SVT systems, and one ternary EZB/
SVT/FEN system were established by both experimental
(calorimetric studies) and theoretical (Schröder−Van Laar
equation) approaches. The obtained data reveal that all
investigated systems can form eutectic concentrations. The
concentration at which a single melting endotherm was
registered in EZB/SVT, EZB/FEN, SVT/FEN, and EZB/
SVT/FEN was 35 wt % of EZB, 10 wt % of EZB, 20 wt % of
SVT, and 20 wt % of SVT and 70 wt % of FEN, respectively. It
is worth highlighting that the measured ternary system’s
eutectic point is in the vicinity (±15%) of the proposed
therapeutic concentration of EZB/SVT/FEN. What can
slightly explain why, in the proposed therapeutic concen-
tration, the marvelous effect was noted in clinical trials. Based
on the obtained data, it would be fascinating to check the
medical effectiveness of the EZB10/SVT20/FEN70 (i.e.,
eutectic) composition.
The second aim of our studies was to convert the
representative ternary EZB/SVT/FEN concentrations into
amorphous form and investigate their physicochemical proper-
ties together with the impact of additives on the mixture’s
physical stability. As has been demonstrated, all analyzed
samples are characterized by a single glass transition event
suggesting a lack of phase separation. Tg of the ternary systems
changes from 254 to 333 K, depending on the component’s
ratio. Since during the nonisothermal calorimetric studies, the
lack of sample devitrification was observed, when both 5 and
10 K/min heating rate were employed, one can conclude that
neat EZB and FEN’s physical stability improves in the presence
of the other APIs. The time-dependent dielectric studies,
which were performed when samples were stored at isochronal
conditions, revealed that the amorphous system corresponding
to the eutectic concentration is characterized by the highest
physical stability. This result suggests that specific interactions,
which on the one hand are responsible for the formation of
eutectics in crystalline mixtures, play a significant role in
improving the physical stability of their amorphous counter-
parts.
Because of the fact that pharmaceuticals are usually stored
under standard storage conditions (i.e., Troom and RH = 40%),
the last step of our studies was dedicated to the long-term
physical stability studies of eight selected ternary compositions
of EZB/SVT/FEN. The XRD experiment confirmed the
previously observed high physical stability of the system
EZB10/SVT20/FEN70 (i.e., having concentration corre-
sponding to the eutectic mixture). The presented findings
strongly suggest that it would be interesting to investigate the
medical effectiveness of both ternary crystalline and ternary
amorphous EZB/SVT/FEN systems having a eutectic
concentration in comparison to one that is proposed in the
literature. Furthermore, the obtained results open up a new
way of selecting the therapeutic concentrations for combined
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